Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies

Bispecific antibodies can create purification challenges that conventional monoclonal antibody platform polishing is not always equipped to solve, with product-related variants “misbehaving” and closely resembling the desired heterodimer. Effective and efficient process development depends not only on identifying the appropriate selectivity from a toolbox of chromatography resins, but also how efficiently complementary unit operations interconnect for manufacturing.

In this GEN webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study. She will compare alternative process configurations and examine the purity, recovery, and process-performance tradeoffs used to identify a preferred downstream polishing train. Key takeaways from the webinar include:

• A systematic approach to screening polishing resins for bsAbs
• Strategies for matching resin selectivity to key impurities
• Insights into how polishing resin selection affects process performance
• Criteria for balancing purity, yield, loading, and robustness

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Produced with support from: